# DESCRIPTION

## FIELD

- relate to recombinant production of IgA proteases

## BACKGROUND

- introduce IgA proteases
- describe IgA protease function
- discuss limitations of previous production methods
- motivate need for improved production methods

## SUMMARY

- summarize recombinant production of IgA proteases
- describe expression of IgA protease polypeptides
- introduce host cells and vectors
- describe soluble and active IgA protease production
- summarize increased yield of soluble IgA protease
- describe culturing of host cells
- introduce IgA protease polypeptides lacking alpha and beta domains
- describe soluble protease productivity levels
- summarize increased yield of active IgA protease
- describe host cell growth conditions
- introduce bacterial IgA proteases
- describe IgA protease identity
- summarize host cell selection
- describe vector selection

## DETAILED DESCRIPTION

- describe recombinant IgA protease production

### Definitions

- define technical terms
- specify reference sources
- define "a", "an", and "the"
- define "about" and "approximately"
- define "ambient temperature" and "room temperature"
- define "cDNA"
- explain polynucleotide sequence notation
- define "complementary"
- define "conservative substitution"
- define "derivative" in reference to polypeptides
- define "effective amount" and "therapeutically effective amount"
- define "encoding"
- define "expression control sequence" and "expression vector"
- define various other terms
- define heterologous sequence
- define pharmaceutical composition
- define pharmaceutically acceptable carrier, diluent or excipient
- define pharmaceutically acceptable salt
- define polynucleotide
- define polypeptide
- define primer
- define recombinant polynucleotide
- define hybridizing specifically to
- define stringent conditions
- define subject of diagnosis or treatment
- define substantially homologous or identical
- describe sequence comparison algorithms
- describe BLAST algorithm
- define substantially pure and isolated
- define treat, treating, and treatment
- define prevent, preventing, and prevention
- define therapeutic treatment

### IgA Protease Polypeptides

- introduce IgA proteases
- describe serine-type IgA proteases
- summarize IgA protease families
- list exemplary IgA proteases
- describe production limitations
- summarize previous cloning attempts
- introduce alternative production methods
- describe expression of truncated IgA proteases
- outline advantages of inclusion bodies
- introduce IgA protease polypeptides
- describe recombinant production
- specify host cells
- detail expression vectors
- explain signal peptides
- describe tags for detection and purification
- provide host cell compositions
- outline large-scale production methods
- specify productivity levels
- describe methods to increase solubility
- detail amounts of active protein produced

### Derivatives of IgA Protease Polypeptides

- define polypeptide derivatives
- describe PEGylation of IgA protease
- summarize PEG group attachment methods

### IgA Deposition Disorders

- introduce IgA deposition disorders
- describe IgA nephropathy
- summarize other IgA deposition disorders
- discuss animal models for IgA nephropathy

### Pharmaceutical Compositions of IgA Proteases and Methods of Using IgA Proteases

- define pharmaceutical compositions of IgA proteases
- describe IgA protease pharmaceutical compositions with excipients, diluents, and carriers
- specify active IgA protease purity levels
- list non-limiting examples of excipients, carriers, and diluents
- describe buffer solutions and buffering agents
- specify pH ranges for compositions
- describe isotonicity-adjusting agents
- list non-limiting examples of preservatives
- describe stabilizers
- discuss pharmaceutically acceptable salts
- describe various dosage forms (e.g., tablets, capsules, granules, powders)
- discuss oral administration formulations
- describe parenteral administration formulations
- discuss lyophilized formulations
- describe kits containing IgA protease compositions
- define therapeutically effective amounts of IgA proteases
- discuss dosing frequencies
- describe modes of administration (e.g., injection, infusion, oral, topical)
- discuss depot formulations and implantable devices
- describe combination therapy with other active agents
- discuss simultaneous and sequential administration of IgA proteases and other active agents
- describe kits containing IgA protease compositions and other active agents
- provide instructions for preparing and administering IgA protease compositions

### Representative Embodiments of the Disclosure

- describe method for producing IgA protease
- specify host cell and vector requirements
- detail IgA protease polypeptide characteristics
- outline solubilization and refolding process
- specify chaotropic agents and concentrations
- describe refolding buffers and pH ranges
- outline additional refolding buffer components
- specify refolding temperatures and concentrations
- describe washing and purifying inclusion bodies
- outline purification methods for refolded IgA protease
- describe representative embodiments of the disclosure
- specify ratio of soluble IgA protease to total IgA protease
- describe fold increase in IgA protease production
- describe purification methods for IgA protease
- specify bacterial IgA protease and IgA1 protease
- describe identity of IgA protease to SEQ ID NO
- describe host cell and culture conditions
- describe IPTG-inducible vector and IPTG concentration
- describe plasmid and promoter
- describe signal peptide and IgA protease polypeptide
- describe pharmaceutical composition and host cell composition

## EXAMPLES

### Example 1

- introduce IgA1 protease production problem
- describe previous attempts at production
- generate IgA1 protease expression constructs
- express constructs in different E. coli strains
- screen for soluble IgA1 protease expression
- detect IgA1 protease expression with Western blot
- detect IgA1 protease activity with Western blot
- express IgA1 protease in E. coli C41(DE3) cells
- screen soluble IgA1 protease expression with ELISA
- analyze IgA1 protease expression in different cell strains
- analyze IgA1 protease expression at different temperatures
- summarize results of IgA1 protease expression

### Example 2

- describe direct production of soluble IgA1 protease
- express IgA1 protease in E. coli C41(DE3) cells
- isolate soluble IgA1 protease
- purify soluble IgA1 protease with nickel column
- purify soluble IgA1 protease with anion-exchange column
- purify soluble IgA1 protease with size-exclusion column

### Example 3

- clone IgA1 protease gene
- express IgA1 protease in E. coli
- induce IgA1 protease expression with IPTG
- confirm IgA1 protease expression by Western blot
- express and isolate IgA1 protease inclusion bodies
- solubilize inclusion bodies with urea or guanidine hydrochloride
- screen refolding conditions for IgA1 protease
- refold solubilized inclusion bodies by dilution method
- purify refolded IgA1 protease by Ni-NTA column chromatography
- dialyze and further purify refolded IgA1 protease
- isolate and solubilize inclusion bodies on a larger scale
- refold solubilized inclusion bodies on an IMAC column
- elute and purify refolded IgA1 protease from IMAC column
- evaluate IgA1 protease refolding by size-exclusion column chromatography
- assay IgA1 protease activity using Experion automated electrophoresis system
- compare purity and activity of refolded IgA1 protease to soluble IgA1 proteases
- summarize results of IgA1 protease expression, refolding, and purification

### Example 4

- express IgA1 protease in E. coli BL21(DE3) cells
- harvest and lyse cells to release inclusion bodies
- collect inclusion body pellet by centrifugation
- wash inclusion bodies with detergent and centrifugation
- wash inclusion bodies with automated microfiltration/crossflow filtration system
- solubilize inclusion bodies with urea or guanidine hydrochloride
- refold solubilized inclusion bodies with arginine
- ultrafiltrate and diafiltrate refolded IgA1 protease
- purify refolded IgA1 protease with nickel column
- elute IgA1 protease from nickel column with imidazole
- purify IgA1 protease with Q sepharose column
- elute IgA1 protease from Q sepharose column with NaCl
- purify IgA1 protease with S300 Sephacryl HR size-exclusion column
- elute IgA1 protease from S300 column with TBS
- automate washing, solubilization, and refolding with AKTAcrossflow apparatus
- discuss advantages of present methods over previous attempts
- discuss potential reasons for success of present methods
- discuss potential applications of IgA proteases produced by present methods

